Genetic depletion and pharmacological inhibition of JNK have been found impactful in AD in vivo model phenotypes (Bogoyevitch et al., 2004; Bowers et al., 2011; Probst et al., 2011; Ramin et al., 2011; Hong et al., 2012; Zhou et al., 2015; Petrov et al., 2016; Gourmaud et al., 2018). Here, MAPK8 is linked to Alzheimer disease.